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Dendritic cells (DCs) play a central role in shaping immunogenic as well as tolerogenic 
adaptive immune responses and thereby dictate the outcome of adaptive immunity. 
Here, we report the generation of a CD8α+ DC line constitutively secreting the tolerogenic 
cytokine interleukin (IL)-35. IL-35 secretion led to impaired CD4+ and CD8+ T lymphocyte 
proliferation and interfered with their function in vitro and also in vivo. IL-35 was further-
more found to induce a tolerogenic phenotype on CD8α+ DCs, characterized by the 
upregulation of CD11b, downregulation of MHC class II, a reduced costimulatory potential 
as well as production of the immunomodulatory molecule IL-10. Vaccination of mice with 
IL-35-expressing DCs promoted tumor growth and reduced the severity of autoimmune 
encephalitis not only in a preventive but also after induction of encephalitogenic T cells. 
The reduction in experimental autoimmune encephalitis severity was significantly more 
pronounced when antigen-pulsed IL-35+ DCs were used. These findings suggest a new, 
indirect effector mechanism by which IL-35-responding antigen-presenting cells con-
tribute to immune tolerance. Furthermore, IL-35-transfected DCs may be a promising 
approach for immunotherapy in the context of autoimmune diseases.
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inTrODUcTiOn
The immune system has to cope simultaneously with foreign substances while maintaining tolerance 
to self-antigens. Dendritic cells (DCs) play a dual role in linking and integrating innate and adap-
tive immune responses. Due to their central role, DCs are particularly interesting targets for novel 
immunotherapeutic approaches for the specific treatment of autoimmune diseases.
Interleukin (IL)-35 is a heterodimeric protein composed of a P35 (Il12a) and an Ebi3 (Il27b) chain. 
IL-35 is described to be produced predominantly by natural regulatory T (Treg) as well as CD138+ 
plasma cells (1, 2). Administration or over-expression of IL-35 has been shown to confer protection 
to the development of various experimental autoimmune diseases through the suppression of CD4+ 
T cell proliferation and function. IL-35 furthermore induces a distinct subset of Foxp3− Treg (iTr35) 
and B cells (1, 2). More recently, IL-35 has been shown to be involved in the maintenance of tolerance 
Abbreviations: actTGF-β, active TGF-β; DC(s), dendritic cell(s); MuTu DC, murine tumor DC line; iTr35, IL-35-expressing 
regulatory T cell.
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in the intestinal tract (1, 3). In addition, EBI3, but not IL-27p28, is 
expressed in different human cancers like Hodgkin lymphoma or 
nasopharyngeal carcinoma cells (4, 5). IL-35 production has not 
only been implicated in neoplastic but also in tumor-associated 
cells, suggesting a more diverse production and function than 
initially proposed (6, 7). Despite these recent insights, the biologi-
cal relevance for immunoregulation as well as the exact function 
of the cytokine IL-35, especially on non-lymphoid cells, remains 
elusive.
We previously described a stable CD8α+ DC line [murine 
tumor DC line (MuTu DC)] (8, 9). This cell line exhibits 
phenotypical and functional characteristics of freshly isolated 
CD8α+ DCs, i.e., expression pattern of surface markers, potent 
costimulation, cross-presentation of antigens, and induction of 
cytotoxic responses by CD8+ T lymphocytes (9). MuTu DCs can 
easily be cultured for over a time span of around 40 passages 
in vitro. The MuTu DCs exhibit an immature phenotype with low 
expression of costimulatory molecules, which can be upregulated 
upon activation with toll-like receptor ligands. Intravenously 
injected MuTu DCs accumulate primarily in liver and spleen. 
They are, however, rejected in a CD8+ T cell-dependent manner 
within 5  days after transfer. By contrast, adoptive transfer into 
rag-deficient or SV40lgT transgene tolerant mice as well as into 
wild-type mice depleted of CD8 T cells leads to development 
of MuTu DC tumors within 1 month (10). The MuTu cell line 
allowed us to investigate the tolerogenic potential of DCs in a 
rational and standardized way. Our results demonstrate that the 
expression of IL-35 potently regulates CD4+ as well as CD8+ T cell 
responses in vitro and also in in vivo. We could further show that 
CD8α+ DCs respond to IL-35 signaling by acquiring a tolerogenic 
phenotype. Antigen pulsing of the IL-35-expressing MuTu DC 
line was further shown to ameliorate autoimmune encephalitis 
in a preventive as well as in a therapeutic setting. Our experi-
ments indicate this effect to be, at least partially, dependent on 
interactions with IL-35-conditioned DCs. These findings suggest 
a novel, indirect mechanism by which IL-35 modulates adaptive 
immune responses.
aniMals anD MeThODs
Mice
C57BL/6, BALB/c, and RAG1−/− C57BL/6 mice were purchased 
from Harlan laboratories. OT-I and OT-II transgenic mice were 
maintained and bred in our own facility. All animals were kept 
and bred in a specific pathogen free animal facility. For all experi-
ments, female, age-matched (6–8  weeks) mice were used. All 
animal experiments were performed after approval by the can-
tonal veterinary office (Service de la consommation et des affaires 
vétérinaires, Département du territoire et de l’environnement, 
Permission no. VD2490.1).
generation of il-35+ MuTu Dc line
Murine tumor DC lines are derived from splenic tumors isolated 
from transgenic CD11c:SV40LgT C57BL/6 mice (8). Their phe-
notypical and functional characteristics have been thoroughly 
described by Fuertes Marraco et al. (9) and Duval et al. (10). A 
single-chain IL-35 construct, consisting of Ebi3 (Il27b) and p35 
(Il12a), linked by (Gly4Ser)3 was amplified from mouse DCs, 
respectively, IL-12 expression vector (courtesy by B. Becher, 
Zürich) and cloned into pRRLSIN.cPPT.PGK-GFP.WPRE 
lentiviral expression vector (courtesy by D. Trono, Lausanne). 
The reading frame of Ebi3-(Gly4Ser)3-P35 was sequenced to 
exclude mutations. Lentiviral particles containing either an 
empty or an IL-35 expression vector were produced in 293T 
HEK cells. Wild-type MuTu DC line was stably transduced 
with either empty vector (mock DC) or IL-35 lentiviral particles 
(IL-35+ DC) (MOI =  20) and the cells maintained in  vitro for 
maximally 15 passages. Transgene expression was confirmed 
after each transduction by RT-PCR using the following prim-
ers: Ebi3: 5′-ATGTCCAAGCTGCTCTTCCT-3′ (forward), 
5′-AGAGGAGTCCAGGAGCAGTC-3′(reverse). P35: 5′-AAA 
TGAAGCTCTGCATCCTGC-3′(forward), 5′-TCACCCTGTTG 
ATGGTCACG-3′ (reverse). All MuTu DC lines were cultured 
in IMDM–Glutamax (GIBCO) supplemented with 10% heat-
inactivated fetal calf serum, 10  mM HEPES (GIBCO), 50  µM 
β-mercaptoethanol (GIBCO), 50  U/ml of penicillin, and 
10 µg/ml streptomycin (GIBCO) at 37°C in 5% CO2 atmosphere.
il-35 immunoprecipitation
Interleukin-35 was precipitated from cell lysate using IL-12p35-
specific antibodies (R&D systems, clone #45806) and protein 
A/G beads (Santa Cruz Biotechnology). Western blotting was 
conducted as described previously. In brief, cell lysates were cen-
trifuged at 12,000 rpm for 30 min at 4°C. Protein concentrations 
of cell lysates were determined with the BCA assay (Pierce) and 
40 µg of proteins were loaded onto 7.5–15% SDS-polyacrylamide 
gels. The gels were transferred to nitrocellulose membrane 
(Amersham Pharmacia Biotech). The blot was blocked in block-
ing buffer (5% non-fat dry milk/1% Tween 20 in PBS) for 2  h 
at room temperature and then incubated with Ebi3-specific 
antibody (Shenandoah Biotechnology, clone V1.4H6.29) in TBST 
overnight at 4°C. The blot was incubated with HRP-coupled sec-
ondary antibody for 2 h at room temperature. Blot was visualized 
by ECL (Pierce Biotechnology).
T cell Proliferation assays
Mixed Leukocyte Reaction (MLR)
BALB/c responder cells were isolated from spleen and popliteal 
lymph nodes using 40-µm cell strainer. CD4+ and CD8+ T cells 
were purified by immunomagnetic bead-based sorting following 
protocol supplied by the manufacturer (Miltenyi Biotec). Then, 
1  ×  105 responder T cells were stained with 5  µM efluor670 
proliferation dye (eBioscience) and cocultivated with either 
control DCs, IL-35+ DCs, or syngeneic CD4+ or CD8+ depleted 
splenocytes at different ratios in 96-well U-bottom plates. 
T cell proliferation and activation were assessed after 3 days by 
flow cytometry and IL-35 mRNA expression was measured by 
RT-PCR.
iTreg Suppression Assay
Suppression assays were performed as described by Collison and 
Vignali (11). Briefly, 1 × 105 IL-35+ DCs or mock DCs were plated 
in a 24-well plate and incubated overnight. DCs were activated 
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with CpG and polyI:C for 6 h. CD4+ T cells were magnetically 
isolated from C57BL/6 mice using the naïve CD4+ T cell isolation 
kit (Miltenyi) and plated at a 10:1 (1 × 106 cells) ratio to mock 
or IL-35+ DCs. A 2 ng/ml recombinant TGF-β and a 10 ng/ml 
IL-2 were added to some of the wells containing mock DCs for 
the generation of Foxp3+ Tregs. Cells were incubated for 4 days. 
Different amounts of the generated suppressor T cells were then 
seeded with 2.5 × 104 efluor670 proliferation dye stained naïve 
target CD4+ T cells. Proliferation of the target cells was assayed 
after 3 days. Percent suppression was calculated using the follow-
ing formula: 
% %proliferated Tconv alone proliferated Tconv
             
−
                treated with Treg
proliferated Tconv alon% e
×100.
In Vitro OT-I/II Proliferation
The 5 × 104 cells of the respective MuTu DC line were pulsed for 
4 h with different concentrations of ovalbumin-specific peptides 
SIINFEKL (OT-I) or OVA329–337 (OT-II). CD8+ or CD4+ T cells 
were magnetically isolated from OT-I/Rag−/− or OT-II/Rag−/− 
mice, respectively and stained with 5 µM efluor670 proliferation 
dye (eBioscience). Then, 1 × 105 T cells were cocultured with the 
DCs for 3 days when the non-adherent T cells were harvested and 
analyzed by flow cytometry and real-time PCR.
In Vivo OT-I/II Proliferation
CD8+ or CD4+ T cells were magnetically isolated from CD45.1+ 
OT-I/Rag−/− or OT-II mice, respectively and stained with 5 µM 
efluor670 proliferation dye (eBioscience). The 2 ×  105 T cells 
were intravenously injected into CD45.2 C57BL/6 mice. Then, 
2.5 × 106 cells of the respective CD8α+ DC line were pulsed with 
either SIINFEKL (OT-I restricted, 1 µg/ml) or OVA329–337 (OT-II 
restricted, 50 µM) peptide and were i.v. injected on the same day 
and 1 day after T cell transfer. Mice were sacrificed 4 days later 
and the isolated splenocytes were analyzed by flow cytometry.
Tumor experiments
B16.F0 melanoma and CMT93 colon carcinoma tumor cell 
lines were cultured in DMEM medium (GIBCO), supple-
mented with 10% FCS, and 50 U/ml of penicillin and 50 mg/
ml streptomycin (GIBCO). Tumor cell lysate was generated by 
five consecutive freeze/thaw cycles in liquid nitrogen. Lysate 
was centrifuged at 1500  g for 15  min before use. Mock- or 
IL-35-transduced DCs were pulsed with respective lysate in a 
1:4 lysate to DC ratio and 100 U/ml IFN-γ (eBioscience). Five 
and three days before and three days after tumor cell transfer, 
2.5 × 106 DCs were s.c. injected in the flank. Tumor was induced 
by s.c. injection of 2 × 105 B16.F0 or 2 × 106 CMT93 cells into 
the same flank. Tumor growth was followed by measuring 
length and width using a caliper. Tumor volume was measured 
using the formula V = ⋅ ⋅ ⋅( )pi
6
1 58
3
2. length width  as described by 
Wurzenberger et al. (12).
Flow cytometry
The fluorochrome-conjugated antibodies used were specific 
to CD11c (clone N418, PECy7), GR1 (clone RB6-8C5, PE, or 
PerCP-PECy5.5), CD8a (clone 54-6.7, FITC, or APC-Cy7), 
DEC205 (clone 205yekta, PerCP-eF710), CD24 (cloneM1/69, 
PerCP-Cy5.5), Clec9A (clone 42D2, PE), CD11b (clone M1/70, 
APC), CD3 (clone 500A2, ef450), CD4 (clone RM4-5, APC, eF450), 
MHCI (clone AF6-88.5.5.3, APC), MHCII (clone M5/114.15.2, 
PE), CD40 (clone 1C10, APC), CD80 (clone 16-10A1, PECy5), 
CD86 (clone GL1, APC, or Alexa750), panNK (clone DX5, FITC), 
Ly6C (clone HK1.4, APC), and Ly6G (clone 1A8, PerCP-Cy5.5). 
For intracellular staining, the T cells were restimulated for 4 h 
with 10 ng/ml PMA and 500 ng/ml Ionomycin, in the presence of 
10 µg/ml Brefeldin A. After extracellular staining, cells were fixed 
for 30 min in 4% paraformaldehyde and permeabilized in 0.5% 
Saponin buffer for 30 min. Intracellular staining was performed 
in Saponin buffer for 30  min. All antibodies were acquired 
from eBioscience or Biolegend. Flow cytometric analyses were 
performed on LSRII cytometer (Becton Dickinson) using FACS 
Diva6 (Becton Dickinson) and FlowJoX (Tree Star) software for 
data processing.
induction of adoptive Transfer 
experimental autoimmune  
encephalitis (eae)
Adoptive transfer EAE was induced as described by Miller and 
Karpus (13). Briefly, myelin oligodendrocyte glycoprotein (MOG) 
reactive T cells were primed in donor C57BL/6 mice by two sub-
cutaneous injections of MOG35–55-peptide emulsified in complete 
Freud’s Adjuvant (Sigma). Intraperitoneal injection of 200  ng 
Pertussis Toxin (Sigma) was used to boost lymphocyte priming. 
In order to study the effect of tolerogenic molecules, MOG35–55 
peptide-pulsed DCs were intravenously injected 1 day before and 
1 day after the immunization. Twelve days post immunization, 
inguinal, brachial, and axillary lymph nodes were isolated by 
digestion in 1 mg/ml Collagenase D (Roche) for 20 min at 37°C. 
Single cells suspension was prepared using a 40-µm cell strainer 
(Falcon). Lymph node cells were expanded in vitro for 3 days in 
the presence of MOG35–55-pulsed DCs and 0.5 ng/ml recombinant 
IL-12p70 (eBioscience). Then, 5 × 106 MOG-specific T cells were 
then transferred to C57BL/6 recipient mice by i.p. injection. Mice 
were i.v. injected with MOG35–55-pulsed DCs 1  day after T cell 
transfer. Clinical EAE symptoms were scored daily in a blinded 
manner: 0—no obvious changes in motor functions; 1—decreased 
tail tonus; 2—abnormal gait (ataxia and/or impaired righting 
reflex); 3—partial hind limb paralysis; 4—complete hind limb 
paralysis; and 5—complete hind and fore limb paralysis.
gene expression analysis  
by real-time Pcr
Total RNA was isolated from the cells and purified using the 
RNeasy® spin columns following the manufacturer’s protocol 
(Qiagen). Total RNA yields were quantified by Nanodrop spectro-
photometry (Thermo Fisher Scientific). Synthesis of cDNA was 
performed using random nonamer primers and the Superscript II 
Reverse Transcriptase kit (Invitrogen). cDNA was purified using 
the PCR clean-up kit (Qiagen) and stored at −80°C.
Real-time PCR (RT-PCR) was performed in technical 
triplicates using SYBR FAST qPCR mix (KapaBiosystems) 
FigUre 1 | interleukin (il)-35-transduced dendritic cells (Dcs) upregulate cD11b and do not respond to activation stimuli. IL-35- and mock-transduced 
DCs were cultured under equal conditions and analyzed by flow cytometry for the expression of panel (a) DC-specific markers or panel (B) activation markers upon 
12 h stimulation with 5 µg/ml CpG and 1 µM pI:C. Data representative of four independent experiments. (c) IL-35- or control-transduced DCs were seeded and 
incubated for 3 days. The cells were stimulated as described above for the last 12 h or not and the secretion of the indicated cytokines was quantified by ELISA. 
Results indicated as the mean of biological triplicates ± SD. Data representative for one of six independent experiments.
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and 5  ng RNA/reaction on a LightCycler480 machine (Roche 
Diagnostics). Relative expression levels were analyzed using 
qBase+ 1.2 data analysis software (BioGazelle). Gene expression 
for each individual sample was normalized to the housekeeping 
genes HPRT 5′-AGCCTAAGATGAGCGCC-3′ (forward) and 
5′-TTACTAGGCAGATGGCCACA-3′ (reverse) and β-actin 
5′-GCACAGCTTCTTTGCAGCTCCTTCG-3′ (forward) and 
5′-TTTGCACATGCCGGAGCCGTTG-3′ (reverse).
statistical analysis
Differences between groups were determined using either 
unpaired two-tailed Student’s t-test or Mann–Whitney U test 
where indicated. All statistical analyses were performed using 
Prism 6.0 (GraphPad). p-Values are indicated when considered 
statistically significant (*p ≤ 0.05, **p ≤ 0.005, ***p ≤ 0.001).
resUlTs
il-35 inhibits Upregulation of Mhc  
class ii and costimulatory Molecules  
by cD8α+ Dcs upon activation
A stable murine DC line, constitutively expressing a biologi-
cally functional, single-chain IL-35 construct (Supplementary 
Figure  1A) was generated by lentiviral transduction of the 
recently established CD8α+ MuTu DC line (thereafter named 
“wtDC”) (9). Il12p35 and Ebi3 transcripts were detected via 
quantitative PCR (Supplementary Figure  1B). Ebi3 protein 
expression was confirmed by western blot of the cell lysate of 
cultured IL-35-expressing DCs after immunoprecipitation using 
anti-IL-12p35 antibody (Supplementary Figure  1C). For the 
remainder of this manuscript, the IL-35-expressing MuTu DC 
line is referred to as “IL-35+ DC.”
Additionally, empty vector-transduced DCs (mock DCs) 
were generated and used as controls when appropriate. We could 
not observe any noticeable differences in the morphological 
characteristics or the proliferative capacity when comparing 
the wtDC line to the lentivirally transduced MuTu DC lines. 
Six independent transductions of MuTu DCs were conducted 
yielding IL-35-expressing DCs with comparable functional 
and phenotypic properties. The IL-35+ MuTu DC cell line was 
assessed for the expression of a panel of surface markers com-
monly used to characterize CD8α+ DCs by direct comparison 
to mock DCs. Flow cytometric analysis revealed a marked 
reduction of CD11c, CD8α, and DEC205 surface expression on 
IL-35+ DCs. By contrast, the expression of CD11b was drastically 
increased (Figure  1A). Furthermore, the IL-35-expressing DC 
line exhibited lower expression of MHC I and MHC II as well as 
5Haller et al. IL-35 Producing DC Induce Tolerance
Frontiers in Immunology | www.frontiersin.org February 2017 | Volume 8 | Article 98
costimulatory molecules CD40 and CD86 (Figure 1B). Activation 
of the control DCs with TLR3 and TLR9 ligands polyI:C and 
CpG led to increased surface expression of MHC II as well as 
costimulatory receptors CD40, CD80, and CD86 by control DCs. 
Conversely, IL-35+ DCs exhibited a complete unresponsiveness 
to TLR stimulation as indicated by the failure to upregulate any 
of the analyzed (co-)stimulatory molecules. Interestingly, IL-35+ 
DCs showed an increased CD80 expression already under resting 
condition when compared to mock DCs. A more than twofold 
reduction in IL-12p40 secretion could be detected by ELISA in 
the culture medium of IL-35+ DCs while the production of the 
immunoregulatory cytokine IL-10 was found to be increased 
significantly (Figure 1C).
In order to investigate whether the observed phenotypic 
change of IL-35+ DCs is provoked by an autocrine effect of the 
transgene, wild-type MuTu DCs were cultured for 4 days in IL-35 
containing culture medium. As observed for IL-35-transduced 
MuTu DCs, IL-35-conditioned wild-type DCs expressed mark-
edly higher levels of CD11b. On the contrary, the expression of 
CD11c, CD8α, and DEC205 was not significantly altered when 
compared to cells cultured in control medium (Figure 2A). Upon 
activation with TLR3 and TLR9 ligands, IL-35-conditioned but 
not control DCs exhibited a significantly impaired upregula-
tion of MHCII and the costimulatory receptor CD40. Similar 
to IL-35+ DCs, IL-35 conditioning increased the expression of 
CD80 already under steady-state conditions and TLR stimula-
tion did not further augment its surface expression (Figure 2B). 
Moreover, upon TLR stimulation, MuTu DCs cultured in IL-35 
supplemented medium secreted significantly less IL-12p40 and 
IL-6 cytokine when compared to DC grown in control medium. 
In contrast to IL-35+ DCs, no increase in IL-10 secretion could 
be detected (Figure 2C).
il-35-expressing MuTu Dcs impair  
T cell Proliferation and Function
We have previously demonstrated that the MuTu DC lines effi-
ciently induce T cell proliferation in MHCI or MHCII restricted 
systems (9). IL-35 on the other hand, is described to inhibit CD4+ 
T cell proliferation (2, 14). We therefore tested whether the IL-35-
producing DC line is able to affect T cell activation and function. 
An allogeneic MLR was performed using variable amounts of 
mock transduced or IL-35 expressing, C57BL/6-derived DCs as 
stimulators. Coculture with mock-transduced DCs resulted in a 
robust, DC number-dependent proliferation of BALB/c-derived 
CD4+ responder T cells. This was accompanied by an increased 
percentage of activated CD44+ CD62L− T cells and IFN-γ-
expressing T cells. On the contrary, target cell proliferation and 
activation were severely reduced when IL-35+ DCs were used as 
activator cells (Figure 3A). Analysis of target T cell RNA revealed 
a significant upregulation of IL-35-associated P35 and Ebi3, but 
not IL-12- or IL-27-specific P40, respectively, P28 transcripts. In 
contrast to IL-35+ DCs, culture with mock-transduced DC led 
to a significant upregulation with IL-12/23-associated P40 but 
not P35 or Ebi3 transcripts (Figure 3B). No single-chain IL-35 
cDNA could be detected by PCR, excluding the possibility of 
a contamination of the RNA by IL-35+ DCs (Supplementary 
Figure 2). Similar results were obtained upon the cotransfer of 
OVA323–339 peptide-pulsed mock or IL-35+ DCs and congenically 
marked OT-II CD4+ T cells into C57BL/6 mice. Four days after 
the transfer, IL-35-expressing but not control-transduced DCs 
were shown to reduce both the amount of detectable CD45.1+ 
OT-II T cells as well as their IFN-γ production (Supplementary 
Figure 3A).
There is only limited information on the effects of IL-35 on 
the proliferation and effector functions of CD8+ T cells available. 
Allogeneic MLR-culturing BALB/c-derived CD8+ T cells with 
C57BL/6 IL-35+ or mock-transduced MuTu DCs were therefore 
performed. We found that IL-35+ but not mock DCs signifi-
cantly reduced proliferation, activation status, as well as IFN-
γ expression by CD8+ T lymphocytes (Figure 3C). IL-35+ DCs 
furthermore induced the transcription of significantly higher 
levels of Ebi3 and P35 in CD8+ T cells than mock-transduced 
DCs (Figure 3D). Similarly, a drastic reduction in the abundance 
of CD45.1+ CD8+ T cells could be observed upon co-injection 
of OT-I CD8+ T cells together with OVA323–339 peptide-pulsed 
IL-35-expressing but not mock-transduced DCs into C57BL/6 
mice (Supplementary Figure 3B). No differences in cell number 
and in IFN-γ expression of host-derived CD45.2+ CD8+ T cells 
were observed (Supplementary Figure 3C).
Interleukin-35 cytokine was originally described to mediate 
infectious tolerance via the induction of a regulatory phenotype 
on naïve CD4+ T cells (14). We therefore tested whether the 
observed induction of P35/Ebi3 transcription by CD4+ T cells 
cocultured with IL-35+ DCs is accompanied with the acquisition 
of suppressive properties. Purified naïve wild-type CD4+ T cells 
were cocultured for 4 days with either IL-35+ DC or mock DCs 
and recombinant IL-2 and TGF-β. A classical suppression assay 
was then performed by culturing the conditioned T cells at dif-
ferent ratios with naïve CD4+ responder T cells in the presence 
of CD3/CD28 stimulation. We could measure a significantly 
reduced, ratio-dependent, responder cell proliferation when 
suppressor T cells were conditioned in the presence of IL-35+ DC 
or mock DC supplemented with IL-2 and TGF-β. No such effect 
was observed when cells were conditioned with mock DC alone. 
However, IL-35+ DC-conditioned T cells consistently proved to 
be more potent suppressors than TGF-β/IL-2-induced Tregs. 
Both in terms of maximal suppressive capability as well as the 
minimal ratio of suppressor T cells needed to observe an inhibi-
tory effect. In accordance with literature, IL-35 induced regula-
tory cells did not express the classical Treg cell marker Foxp3. T 
cells conditioned for 4 days in IL-35 containing medium but in 
the absence of mock DC, did not exert any suppressive functions 
(Figure 4 and data not shown).
il-35-conditioned MuTu Dcs impair  
cD4+ T cell Proliferation and Function
As demonstrated above, IL-35+ DCs as well as wild-type DCs 
cultured in IL-35 containing medium did not adequately 
upregulate MHCII and costimulatory receptors upon activation, 
but remained in a rather immature state with increased CD80 
expression. Such immature DC populations have been described 
to induce and maintain T cell tolerance (15). We therefore con-
sidered the possibility that the observed effects on T cells were 
not only caused directly by the secreted IL-35, but indirectly 
FigUre 2 | interleukin (il)-35 abrogates the immunogenicity of murine tumor Dc lines (MuTu Dcs). Wild-type MuTu DC line was cultured for 4 days in the 
presence of filtered and concentrated supernatant of IL-35 vector-transfected 293T HEK cells. wtDCs incubated with either empty vector-transfected 293T HEK 
cells or normal medium served as controls. (a) Dendritic cells (DCs) were analyzed for expression of DC-specific markers by flow cytometry. (B) wtDCs were 
cultured as described above and activated with 5 µg/ml CpG and 1 µM pI:C (light gray histograms) or not (black histograms). Bar charts summarize fold 
upregulation of the respective activation marker upon activation. Experiments were conducted in biological triplicates and results are shown as the mean of the ratio 
of geometric mean activated cells/geometric mean resting cells ± SD. MFI, mean fluorescence intensity. Data representative for one of five independent 
experiments. (c) Wild-type MuTu DCs were conditioned and activated as described above. The cytokine secretion in the culture medium was assayed by ELISA. 
Data representative for one of three independent experiments. n.d., not detectable. Results depicted as the mean of biological triplicates ± SD.
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through the modulation of the immunogenic potential of the 
conditioned DCs. In order to test this hypothesis, wild-type 
MuTu DCs were conditioned for 3 days in IL-35 containing or 
control culture medium. Upon removal of IL-35, OVA323–339-
pulsed IL-35-conditioned DCs exhibited a significantly impaired 
potential to stimulate OT-II CD4+ T cell proliferation, activation, 
and IFN-γ production when compared to control medium-
conditioned MuTu DCs. The inhibitory effect on CD4+ T cells 
by IL-35-conditioned DCs was found to be comparable to OT-II 
CD4+ T cells stimulated with IL-35+ DCs (Figure 5A). In contrast 
to coculture with IL-35-expressing DCs, no induction of Ebi3 
transcription and only a moderate induction of IL-12p35 were 
FigUre 3 | continued
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FigUre 4 | interleukin (il)-35+ dendritic cell (Dc) cocultured T cells suppress target T cell proliferation. Naïve CD4+ T cells were primed in the presence 
of IL-35+ DCs or mock DCs and 10 ng/ml IL-2/2 ng/ml TGF-β for 4 days. The suppressive capacity of the primed T cells was then assayed by culturing for 3 days 
them with naïve CD4+ responder T cells in the presence of anti-CD3/CD28 stimulation. Results are indicated as mean percent of suppression ± SD. Data 
representative of four independent experiments.
FigUre 3 | continued 
allogeneic stimulation of BalB/c T cells with c57Bl/6 interleukin (il)-35+ dendritic cells (Dcs). Naïve CD4+ T (a,B) or CD8+ T (c,D) cells were isolated 
and magnetically purified from BALB/c mice and cultured for 3 days at different ratios with C57BL/6-derived mock transduced or IL-35+ murine tumor DC lines 
(allogeneic priming) or syngeneic wild-type DCs. (a,c) Proliferation, IFN-γ, and CD44/CD62L expression of the T cells was analyzed by flow cytometry after 3 days. 
(B,D) T cells were isolated and the transcription of IL-12 cytokine family-associated genes was assessed by real-time PCR. Results representative of three (a,B) and 
two (c,D) independent experiments. Data are depicted as mean ± SD.
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observed by OT-II CD4+ T cells incubated with IL-35-conditioned 
wtDC. Interestingly, IL-35-conditioned DCs as well as IL-35+ 
DCs transcribed significantly less of the IL-27-associated p28 
chain than control DCs (Figure 5B).
Taken together, the inhibitory effect on T cell proliferation and 
function in vitro and in vivo demonstrated that IL-35 transgenic 
DC line efficiently interfered with proliferation of both, CD4+ and 
CD8+ T cells. Furthermore, IL-35+ DC impaired the function of 
CD4+ T cells. Our findings further indicate that IL-35 secretion 
alone does not only directly affect T cell proliferation and function 
but also indirectly via the induction of a tolerogenic phenotype 
on MuTu DCs.
Vaccination with il-35+ Dcs Promotes 
Tumor growth
Interleukin-35 has been shown to promote tumor progression 
by interfering with tumor-directed immune responses in several 
human cancers (6, 16, 17). In order to determine whether IL-35+ 
DCs affect T lymphocyte-dependent antitumor responses in vivo, 
C57BL/6 mice (n = 5 per group) were vaccinated a total of three 
times with tumor cell lysate pulsed, IFN-γ-stimulated DCs. Five 
days after first vaccination 2 × 105 B16.F0 melanoma cells were 
transferred subcutaneously into the flank of the mice (Figure 6A). 
B16.F0 tumor volume increased progressively and withdrawal 
criteria were reached in median within 20.5 days in PBS-injected 
mice but only 14 days for mice vaccinated with IL-35+ DCs. Mice 
that were vaccinated with control DCs exhibited a slight, but 
not significant delay in tumor growth when compared to PBS-
injected animals (Figure 6B). Flow cytometric analysis of tumor 
tissue showed drastic reduction of tumor infiltration by CD3+ T 
cells in IL-35+ DC-vaccinated mice. In addition, infiltrating CD4+ 
and CD8+ T cells exhibited a significant reduction in IFN-γ pro-
duction. However, no differences in Foxp3+ Treg cells infiltration 
could be observed (data not shown). IL-35+ DC transfer did not 
significantly affect the percentage or composition of infiltrating 
CD11b+ myeloid cells (Figure 6C). We next sought to determine 
whether IL-35-conditioned DCs contribute to the accelerated 
increase in tumor volume. B16.F0 growth was compared upon 
vaccination with either unpulsed or tumor lysate pulsed, IFN-γ-
activated IL-35+ DCs. Only the transfer of tumor lysate loaded 
IL-35+ DCs but not unpulsed IL-35+ DCs caused a significant 
increase in tumor volume (Figure 6D).
Similarly, subcutaneously transferred CMT93 carcinoma cells 
showed progressive tumor growth in IL-35+ DC-vaccinated mice 
and tumor volume was significantly bigger when compared to 
control animals (Supplementary Figure  4A). In accordance to 
our observations in the B16.F0 model, flow cytometric analysis 
of CMT93 tumor infiltrating leukocytes revealed a markedly 
decreased accumulation of total CD3+ T lymphocytes in IL-35+ 
DC-treated mice. Both CD4+ and CD8+ T cells produced 
significantly less IFN-γ. In contrast to the B16.F0 model, vac-
cination with IL-35+ DCs was furthermore accompanied with 
an increased infiltration by CD11b+ Gr1+ myeloid-derived 
FigUre 5 | interleukin (il)-35-conditioned wild-type dendritic cells (Dcs) impede T cell function. Wild-type murine tumor DC lines were conditioned in 
IL-35 containing or control culture medium. After 3 days, the DCs were pulsed with 50 nM OVA323–339 peptide and cultured with CD4+ OT-II T cells in the absence of 
IL-35. (a) OT-II cells were harvested after 3 days, and proliferation, IFN-γ production, and activation were assessed by flow cytometry. (B) The transcription of IL-12 
cytokine family-associated genes by the OT-II cells was analyzed by real-time PCR. The data represent the mean ± SD of biological triplicates of one of three 
independent experiments.
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suppressor cells when compared to control DC-vaccinated ani-
mals (Supplementary Figure 4B).
Transfer of il-35+ MuTu Dcs interferes 
with Development of eae
In order to assess the potential of IL-35+ DCs to abrogate 
autoimmune T cell activity in  vivo, adoptive transfer EAE 
was induced as described in Section “Animals and Methods.” 
Adoptive transfer allowed us to introduce IL-35+ DCs into 
the experimental system either already during priming of the 
encephalitogenic lymphocytes (experimental groups 2 + 3) or 
only in already diseased recipient mice (experimental groups 
4 + 5) (Figure 7A). After in vivo priming, T cells were restimu-
lated in vitro as depicted in Figure 7A. T cells restimulated with 
myelin oligodendrocyte glycoprotein-35–55 (MOG35–55)-pulsed 
FigUre 6 | interleukin (il)-35-expressing dendritic cells (Dcs) promote tumor growth. (a) C57BL/6 mice were intravenously vaccinated a total of three 
times with 2.5 × 106 tumor cell lysate pulsed, IFN-γ-activated IL-35+ DCs, unpulsed IL-35+ DCs, mock DCs, or PBS. Then, 2 × 105 B16F0 melanoma cells were 
transferred subcutaneously in the flank of the animals. (B,D) Tumor growth was measured regularly using a caliper. Results are expressed as the mean of tumor 
volumes ± SD from one of three (B) and two (D) independent experiments (n = 5 per experimental group). Tumor volume in mice that received tumor lysate pulsed 
IL-35+ DCs was significantly increased when compared to panel (B) pulsed mock DC or panel (D) unpulsed IL-35+ DC (*p ≤ 0.05, Mann–Whitney U test).  
(c) Tumors were resected 10 days after inoculation and enzymatically digested. The isolated cells were restimulated and tumor infiltrating cells analyzed by flow 
cytometry. The data show representative results from individual mice from one of three independent experiments (n = 5 per experimental group).
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IL-35+ DCs (experimental group 2) exhibited a less activated 
phenotype and produced less IFN-γ than T cells restimulated 
in the presence of MOG35–55-pulsed mock DCs (experimental 
group 1) (Figure 7B). After in vitro restimulation, 5 × 106 T cells 
were transferred into wild-type C57BL/6 mice. The animals were 
surveilled daily for the development of EAE-related symptoms. 
Recipient mice receiving MOG35–55 reactive T cells that were 
primed in the presence of mock DCs (experimental group 1) 
reproducibly exhibited EAE symptoms within 9 days after T cell 
transfer. A maximum disease score of three, corresponding to a 
complete paralysis of the hind limbs, could be observed between 
14 and 18 days after T cell transfer. The animals subsequently 
recovered and no disease symptoms could be observed 25 days 
after the transfer of immunogenic T cells. By contrast, mice 
that received T cells primed and restimulated in the presence 
of MOG35–55 peptide loaded IL-35+ DCs exhibited a drastically 
reduced disease severity (experimental group 2). Animals 
injected with unpulsed IL-35+ DCs (experimental group 3) 
exhibited an intermediate disease course: EAE symptoms were 
less vigorous when compared to the mock DC control group but 
were significantly more severe than in MOG35–55-pulsed IL-35+ 
DC injected mice (Figure 7C). We further assayed whether the 
FigUre 7 | interleukin (il)-35-expressing dendritic cells (Dcs) ameliorate experimental autoimmune encephalitis (eae) pathogenesis. (a) 
Myelin oligodendrocyte glycoprotein (MOG)-specific T cells were primed in the presence of the respective DC lines in C57BL/6 donor mice. Lymph node 
cells were harvested after 12 days and restimulated in vitro for 3 days in the presence of the respective MOG-pulsed DC line and IL-12. Then, 5 × 106 T 
cells were transferred into recipient C57BL/6 mice. And then, 2.5 × 106 of the respective DCs were injected i.v. 1 day later. The table summarizes the 
different treatment regimens for each experimental group (B) Restimulated CD3+ CD4+T cells were analyzed by flow cytometry for the expression of 
CD44/CD62L and IFN-γ/IL-17a. Shown are representative plots of one of three independent experiments. (c) Recipient mice were examined daily using a 
clinical EAE scoring system ranging from 0 (no symptoms) to 5 (complete paralysis). For the sake of clarity, the data of one representative experiment out 
of four are shown in two graphs (n = 5 animals per experimental group). Data denoted as mean ± SD. *p ≤ 0.05 against control group 1. Mann–Whitney 
U test. (D) Brains of recipient mice were harvested on day 13 (average peak disease). Then, 40 µm thick cerebral sections were prepared and infiltrating T 
cells were visualized with CD3 immunohistochemistry and hematoxylin/eosin staining. Arrows depict isolated CD3+ T cell infiltration. Scale bar indicates 
100 µm.
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therapeutic transfer of IL-35+ DCs is sufficient to limit the func-
tion of MOG-primed lymphocytes. Both, in vitro restimulation 
with MOG35–55-pulsed IL-35+ DCs (experimental group 4) or 
the injection of IL-35+ DCs into recipient animals 6 and 8 days 
after the transfer of MOG-primed T cells (experimental group 5) 
slightly delayed the disease onset and led to a significant reduc-
tion of EAE symptoms.
The brains were collected at the peak of disease. Histological 
analysis of sections of the cerebral cortex revealed focal inflam-
matory lesions within the myelin rich regions with a preferential 
perivascular accumulation of CD3+ cells in diseased control 
animals. No formation of such lesions, but only few isolated 
T cells could be observed in the IL-35 experimental group 
(Figure 7D).
DiscUssiOn
Due to their central role in determining the outcome and qual-
ity of adaptive immune responses, DCs are of special interest as 
potential therapeutic tools for the specific treatment of autoim-
mune disease. In contrast to the other members of the IL-12 
cytokine family, IL-35 has been described to inhibit T and B lym-
phocyte proliferation and induce Foxp3−, IL-35-secreting Treg 
cells (iTr35) (14). Recent studies indicate that IL-35 also regulates 
effector functions of plasma cells as well as monocyte-derived 
DCs (18). Although IL-35 seems to contribute essentially to the 
maintenance of immune tolerance and represents a promising 
candidate for immunotherapy, its functionality and tolerogenic 
potential remain poorly investigated.
Recombinant IL-35 has a limited stability, which complicates 
the investigation of this cytokine (19). We thus generated a 
CD8α+ MuTu DC cell line constitutively expressing a single-
chain IL-35 construct. The ectopic expression of IL-35 by the 
MuTu DC line efficiently interfered in  vitro as well as in  vivo 
with CD4+ T lymphocyte proliferation and function. A similar 
effect could be observed when IL-35+ DC were cultured with 
CD8+ T cells. Interestingly, while comparable OT-I and OT-II 
proliferation was observed upon the co-injection with antigen-
pulsed IL-35+ DC in vivo, the number of T cells isolated from 
the mice was greatly diminished. This result suggests that IL-35+ 
DCs might not only affect T cell proliferation but also interferes 
with the survival of the target T cells. DCs have indeed been 
described to mediate apoptosis in activated T cells through 
cytokine regulated expression of Fas ligand (20). As discussed 
below, we assumed the observed effects on T cells might not only 
be a direct effect of IL-35 cytokine produced by the transgenic 
DC line. We furthermore hypothesized additional, IL-35 induced 
effects on the DC itself. IL-35+ DCs induced the expression of 
P35 and Ebi3, the two subunits forming IL-35, by the interact-
ing T cells. Similar to the findings by Collison et  al. (14), the 
IL-35+ DC-conditioned T cells acquired a regulatory phenotype 
as shown by their ability to suppress the proliferation of CD4+ 
T cells. These results provide solid evidence for the functional 
expression of the IL-35 transgene by the DC line. It further 
supports previous findings that IL-35 does not only impair pro-
liferation and effector functions of CD4+ but also CD8+ T cells. 
Interestingly, we observed that IL-35+ DCs but neither IL-35 
containing medium nor IL-35-conditioned DCs alone induced 
the transcription of IL-35 subunits by CD4+ T cells. Moreover, 
in the absence of (co-)stimulation, IL-35-conditioned T cells 
were not capable to suppress naïve target T cell proliferation. 
These results suggest that IL-35 cytokine secretion alone is suf-
ficient to regulate T cell proliferation and function. However, the 
induction of IL-35-expressing iTr35 cells depends on both, TLR 
stimulation and additional stimuli provided by DCs. Others 
have consistently reported that the generation of functional 
iTr35 is dependent on CD3/CD28-mediated activation (14, 
21). Furthermore, CD80/CD86 expression by DCs is necessary 
for the maintenance of Treg cells (22). In the context of IL-35-
mediated propagation of immune tolerance, IL-35-conditioned 
DCs might exert a similar function on Treg cells. We indeed 
observed a consistent upregulation of CD80 when DCs were 
conditioned with IL-35. CD80 upregulation was consistently 
observed, even when DCs were not stimulated by TLR ligands. 
We thus suggest that IL-35 contributes to a semi-mature, tolero-
genic DC (tolDC) phenotype. Low level of antigen presentation, 
the increase in CD80 expression, together with the expression of 
IL-10 might be involved in the generation of iTr35 cells. We have 
shown in this manuscript that IL-35-conditioned DCs acquire 
tolerogenic functions even when IL-35 is removed but without 
IL-35 they cannot induce IL-35 expression in responding T cells. 
However, the molecular basis for this regulatory circuit has yet 
to be elucidated.
Immature or induced tolDCs play an essential role in the 
maintenance of peripheral tolerance by modulating T cell 
activation and inducing Tregs (23). Several mediators like IL-10 
or vitamin D3 have been demonstrated to induce a tolerogenic 
phenotype on DCs. tolDCs are characterized by low levels of 
MHCII and costimulatory markers, as well as a reduced secre-
tion of pro-inflammatory cytokines while expressing tolerogenic 
molecules such as IL-10 or IDO. In addition, the expression of 
CD11b has been associated with a tolDC phenotype (24, 25). In 
our hands, the presence of IL-35 induced a CD11clo CD11bhi, 
MHCIIlo semi-mature phenotype on the MuTu DC line. The 
presence of IL-35 impaired their ability to upregulate the 
expression of MHCII and costimulatory molecules in response 
to stimulation with TLR ligands. TLR ligand activated IL-35+ 
DCs expressed the inhibitory cytokine IL-10 whereas IL-12 
secretion was greatly diminished. A similar shift in cytokine 
production was described by others when CD4+ T cells were 
activated in the presence of recombinant IL-35 (26). The incuba-
tion of TLR ligands activated DCs with IL-35 containing but not 
control culture medium had a similar effect on the expression 
levels of CD11c, CD11b, MHCII, and costimulatory receptors. 
These finding suggest that the IL-35 cytokine directly affects 
the MuTu DCs, maintaining them in a semi-mature state and 
rendering them unresponsive to TLR-activation. In contrast 
to IL-35+ DCs, no IL-10 secretion was detectable when DCs 
were cultured with IL-35 containing medium. This observation 
implies functional disparities between stably transduced and 
IL-35-conditioned DCs which can hardly be addressed with 
our current experimental setup. It is conceivable that IL-35 
induced IL-10 expression requires prolonged signaling or needs 
to exceed a certain signal threshold. We can therefore also not 
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completely rule out that IL-35 induces the expression of second-
ary, unknown mediator(s) which, in turn, drive the observed 
phenotypic changes of the DCs. However, a potential IL-35 
receptor has been postulated to consist either of IL-12Rβ2 and 
IL-6 or IL-27Rα, respectively. Engagement of the receptor was 
demonstrated to result in the activation of STAT1-, STAT3-, or 
STAT4-mediated signaling in T or B cells, respectively (27, 28). 
It was recently shown that IL-35 interferes with the LPS-induced 
activation of MAPK–AP1 pathway in mouse endothelial cells, 
thereby suppressing the expression of various pro-inflammatory 
cytokines and chemokines (29). The potential receptor chains 
are expressed by CD8α+ DCs as well as in most conventional DC 
subtypes (our unpublished data). Thus, a direct effect of IL-35 on 
DCs is at least possible. In addition, both, STAT3 was well as p38/
MAPK-mediated signaling, has been shown to regulate MHCII 
as well as costimulatory receptor expression upon DC activa-
tion. These molecular pathways therefore represent potential 
mediators of IL-35-induced signaling in DCs (30, 31). Further 
investigation is needed to elucidate the composition and expres-
sion of the IL-35 receptors on DCs as well as the downstream 
signaling events driving the observed phenotypic changes in 
IL-35-transduced and IL-35-conditioned DCs.
The IL-35 induced tolerogenic state on wild-type DCs 
translated functionally into an impaired capacity to stimulate 
antigen-specific CD4+ and CD8+ T cell responses. As proposed 
for other tolDC populations, the immature phenotype is 
characterized by low expression of MHCII and costimulatory 
receptors as well as the expression of suppressive molecules 
like IL-10. The addition of IL-10 was described to enhance the 
conversion of naïve CD4+ T cells into iTr35, representing a 
potential mechanism by which IL-35-conditioned DCs con-
tribute to infectious tolerance (14). Human dexamethasone-
induced tolDCs have been described to express both IL-35 
subunits and these are required to elicit their full tolerogenic 
potential (32). It might therefore be possible that DCs can be 
stimulated to produce IL-35 to contribute directly immune 
tolerance. However, the stimuli that trigger IL-35 produc-
tion, aside from IL-35 itself, remain poorly understood. In 
our hands, the conditioning of MuTu DCs with IL-35 did not 
lead to an induction of IL-35-associated genes (unpublished 
observations).
In order to further study the function of the IL-35 induced 
tolDC phenotype, we employed the IL-35+ DC line in two, dif-
ferently immunogenic tumor models. Vaccination with tumor 
lysate pulsed, IL-35-expressing DCs notably accelerated tumor 
growth. This coincided with a reduced tumor infiltration of 
CD4+ and CD8+ T cells and the inhibition of their effector 
functions. A significant acceleration of tumor growth was 
only observed when the IL-35+ DCs were pulsed with tumor 
cell lysate. These observations suggest the inhibition of T cell 
responses to be not only caused by the systemic delivery of 
IL-35 but also by the interaction of antigen-presenting tolDC 
and tumor-specific T cells. Tumor growth in lymphocyte 
deficient RAG2−/− animals was accelerated when compared 
to wild-type animals both upon mock and IL-35+ DC vac-
cination, confirming the involvement of lymphocytes in the 
CMT93 cancer model. In the absence of lymphocytes, tumor 
lysate-pulsed IL-35+ DC vaccination surprisingly led to an 
even faster tumor growth (data not shown). In accordance 
with Wang and colleagues, this indicates that IL-35-mediated 
pro-tumor effect is not solely due to suppression of adaptive 
immunity (6). Our observations and the EAE experiments 
discussed below clearly show that the effect of IL-35 is, at least 
partly, contact dependent. They furthermore imply that the 
observed effects are not merely an effect of reduced MHC class 
II expression.
The administration of tolerogenic cytokines is thought to 
re-establish antigen-specific tolerance through the prevention 
of autoimmune T cell reactivity and expansion of regulatory 
lymphocyte populations. Others have shown the treatment with 
recombinant IL-35 or the ectopic expression of the cytokine by 
different cells to protect mice against a variety of autoimmune 
diseases (1, 33, 34). Furthermore, the intraperitoneal injection 
of IL-35 was recently shown to ameliorate autoimmune patho-
genicity in a murine asthma model partly through the induction 
of an immune-suppressive phenotype on monocyte-derived 
DCs (18). We therefore investigated whether the IL-35+ MuTu 
DC line might be employed to affect the development of the 
CNS autoimmune disease EAE. The preventive transfer IL-35+ 
DCs but not control DCs was found to significantly reduce 
EAE symptoms. The observed effect was found to be mediated 
through the impairment of activation and function of the trans-
ferred CD4+ T cells, resulting in a reduction of CNS infiltration 
and inflammation. This can be only partially attributed to 
the systemic delivery of IL-35 by the IL-35+ DCs itself, as the 
transfer of unpulsed IL-35+ DCs indeed reduced EAE severity. 
However, a further, significant reduction of EAE severity was 
observed only upon loading the IL-35+ DCs with myelin specific 
peptide. These findings suggest the interaction of IL-35+ DCs 
and T lymphocytes to be required for an optimal suppression of 
autoimmunity. Thus, the IL-35 induced immature phenotype of 
the DCs contributes to the observed reduction of EAE severity. 
We therefore propose IL-35-conditioned CD8α+ DCs to con-
tribute indirectly to the IL-35-mediated regulation of adaptive 
immune responses via the adaption of an immature phenotype. 
We further sought to determine the latest time point at which 
the application of MOG-pulsed IL-35+ DCs is capable of affect-
ing EAE development. In vitro restimulation of MOG-primed 
T lymphocytes with IL-35+ DC and also the injection of IL-35+ 
DCs into recipient mice significantly reduced EAE severity. Thus, 
DC transfer, together with the delivery or ectopic expression of 
IL-35 may represent a potential preventive and also therapeutic 
tool for the regulation of pathologic (auto-) inflammation. 
Considering the particular tolerance mechanisms employed by 
IL-35, the combination with other tolerogenic molecules, such 
as TGF-β or IL-10, might potentiate immunosuppressive effects 
in therapeutic settings.
Taken together, our data indicate that IL-35+ MuTu DCs are 
able to exert regulatory functions on CD4+ and CD8+ T cells. 
More importantly, IL-35 was shown to induce a tolerogenic 
phenotype on CD8α+ MuTu DCs, thereby indirectly contrib-
uting to IL-35-mediated immune regulation. Our work adds 
a novel aspect to the functions of this poorly investigated 
cytokine. Further investigation of IL-35 induced effects on 
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DC function, and also on other innate immune cells’ function 
may help us to better understand IL-35-mediated immune 
regulation and to exploit its potential to regulate immune 
responses.
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